Key Highlights The peer-reviewed study, published in Pharmaceutics (MDPI), describes the non-clinical safety pharmacology, toxicokinetics and pharmacodynamics of VMX-C001 in...
Adopted USAN: Reltodecacog alfa has been adopted by the United States Adopted Names (USAN) Council as the non-proprietary name for...
Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company...
Leiden, The Netherlands, 10 september 2024 VarmX, a biotech company focusing on the development of innovative approaches for the reversal...
Leiden, The Netherlands, 26 June 2024 VarmX, a biotech company focusing on the development of innovative approaches for the reversal...
Factor Xa direct oral anticoagulants (Fxa-DOACs) require rapid reversal in patients with serious bleeding or prior to urgent surgery.
...